Entertainment Wire Massachusetts: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Entertainment Wire Massachusetts.

Press releases published on September 8, 2026

Sep. 8, 2026

Edge Marketing CEO Amy Juers to Speak on Leadership, Visibility and Cyber Crisis Response at WIPL 2026

Indeterminate GlobeNewswire

Sep. 8, 2026

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

Indeterminate GlobeNewswire

Sep. 8, 2026

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

Indeterminate GlobeNewswire

Sep. 8, 2026

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Indeterminate GlobeNewswire

Sep. 8, 2026

Liberty Defense Previews the HEXWAVE I-Configuration at GSX 2026 for Entrances That Cannot Give Up a Lane

Indeterminate GlobeNewswire

Sep. 8, 2026

MAX Amphibious ATV Returns to The Price Is Right for Star Trek 60th Anniversary Special

Indeterminate GlobeNewswire

Sep. 8, 2026

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Indeterminate GlobeNewswire

Sep. 8, 2026

Collegium to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 8, 2026

Flare Therapeutics Appoints Peter Lebowitz, MD, PhD, to Board of Directors and Brian DeSchuytner as Chief Financial Officer and Chief Business Officer

Indeterminate GlobeNewswire

Sep. 8, 2026

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

Indeterminate GlobeNewswire

Sep. 8, 2026

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

Indeterminate GlobeNewswire

Sep. 8, 2026

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

Indeterminate GlobeNewswire

Sep. 8, 2026

Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure

Indeterminate GlobeNewswire

Sep. 8, 2026

Liberty Global Agrees to Sell Dutch Towers Ahead of 2027 Ziggo Group Listing

Indeterminate GlobeNewswire

Sep. 8, 2026

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Indeterminate GlobeNewswire

Sep. 8, 2026

CervoMed to Participate in September Investor Conferences

Indeterminate GlobeNewswire

Sep. 8, 2026

Generate Biomedicines Inc. to Participate in September Investor Conferences

Indeterminate GlobeNewswire

Sep. 8, 2026

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

Indeterminate GlobeNewswire

Sep. 8, 2026

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Indeterminate GlobeNewswire

Sep. 8, 2026

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Indeterminate GlobeNewswire